相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL
Jessica T. Leonard et al.
BLOOD (2021)
A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol
Sabina Chiaretti et al.
HAEMATOLOGICA (2021)
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
Robin Foa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
CD4+CD25highCD127low/-FoxP3+ Regulatory T-Cell Population in Acute Leukemias: A Review of the Literature
M. Niedzwiecki et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2019)
T Cell-Activating Bispecific Antibodies in Cancer Therapy
Asaad Trabolsi et al.
JOURNAL OF IMMUNOLOGY (2019)
How I treat Philadelphia chromosome- positive acute lymphoblastic leukemia
Farhad Ravandi
BLOOD (2019)
Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts
Carter M. Suryadevara et al.
CLINICAL CANCER RESEARCH (2019)
Targeting regulatory T cells for improving cancer therapy: Challenges and prospects
Bilikere S. Dwarakanath et al.
CANCER REPORTS (2018)
Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
J. Duell et al.
LEUKEMIA (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Novel immunotherapies in lymphoid malignancies
Connie Lee Batlevi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia
J. -H. Yoon et al.
ANNALS OF ONCOLOGY (2016)
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL
Philippe Rousselot et al.
BLOOD (2016)
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study
Sabina Chiaretti et al.
HAEMATOLOGICA (2016)
The antileukemic potential of natural killer cells
Giovanni F. Torelli et al.
IMMUNOTHERAPY (2016)
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study
Sabina Chiaretti et al.
HAEMATOLOGICA (2016)
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment
Gerhard Zugmaier et al.
BLOOD (2015)
Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells
Giovanni F. Torelli et al.
HAEMATOLOGICA (2014)
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts
Sabina Chiaretti et al.
HAEMATOLOGICA (2013)
Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy
S. Mustjoki et al.
LEUKEMIA (2013)
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Robin Foa et al.
BLOOD (2011)
Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
Dong Hwan Kim et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
S. Mustjoki et al.
LEUKEMIA (2009)
Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy:: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol
Marco Vignetti et al.
BLOOD (2007)
Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets
T Willinger et al.
JOURNAL OF IMMUNOLOGY (2005)
分享论文
